We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Novo Nordisk has settled a patent dispute with Novartis over allegations that the Swiss company infringed on patents for Victoza (liraglutide), Novo Nordisk’s blockbuster type 2 diabetes drug. Read More
The European Medicines Agency’s (EMA) human medicines committee endorsed five new medicines — including a COVID-19 treatment and a gene therapy — during its monthly meeting held from March 21 to 24. Read More
Takeda Pharmaceuticals has received a Complete Response Letter from the FDA denying its Prior Approval Supplement (PAS) application for Natpara (parathyroid hormone) for chronic hypoparathyroidism. Read More
After 14 years of legal wrangling over Fosamax’s bone-fracture risk, Merck has managed to get a federal judge to dismiss in excess of 500 lawsuits charging the drugmaker with staying silent about the dangerous and painful leg breaks the osteoporosis drug was allegedly known to cause. Read More
Just hours before it was to face the start of a trial, Sun Pharmaceuticals of India said it will pay $485 million to settle years-old lawsuits alleging its Ranbaxy Pharmaceuticals subsidiary falsified data to hoodwink the FDA into granting exclusive approvals for its generic drugs, thus delaying competition and making people pay exorbitant prices for the generics. Read More
A coalition of advocacy groups has appealed to Health and Human Services Secretary Xavier Becerra to act unilaterally to lower the prices of six prescription drugs using an obscure and controversial regulatory authority known as “march-in rights.” Read More